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γδ T lymphocytes play an important role in immune reactions towards infections and malignancies. In particular,
Vγ9–Vδ1+ T lymphocytes are thought to play protective antiviral roles in human CMV infection. Recently, Vδ1+
T lymphocytes were proposed to also have anti- B-CLL reactivity. Here we report a case of 48-year-old man who
received allogeneic stem cell transplantation for progressive B-CLL. Within one year after transplantation, lymphoma
relapsed despite a dramatic increase of Vδ1+ T cells in the patient’s blood. In vitro killing assays revealed activity of
patient’s γδ cells against CMV target cells, but not against the relapsing lymphoma-cells. This argues for a
contribution of Vδ1+ cells in the immune reaction against CMV reactivation, but does not support a strong
correlation of expanded Vδ1+ T cells and favorable disease outcome in B-CLL patients.
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Several types of T lymphocytes bearing γδ T cell recep-
tors (TCR) are currently investigated as potential anti-
cancer agents in cell-based immunotherapy. Recently,
Vδ1+ T lymphocytes were shown to be cytotoxic to B-
CLL-derived cell lines [1] and it was proposed that Vδ1+
T lymphocytes may contribute to limiting disease pro-
gression in B-CLL patients [2]. Activated Vδ1+ T lym-
phocytes can produce inflammatory cytokines such as
TNF-α and IFN-γ and can be cytotoxic. Both cytokine re-
lease and cytotoxicity of Vδ1+ T lymphocytes are at least in
part mediated through NKG2D receptor, which recognizes
the stress-induced ligands MIC-A, MIC-B, and ULBP3 on
target cells. At the same time, Vδ1+ T lymphocytes are im-
plicated in the human immune response to cyto-
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reproduction in any medium, provided the orstem cell transplantation as treatment for CLL often en-
counter life-threatening viral infections in the post-
transplant period due to strong immunosuppression.
Thereby, Vδ1+ T lymphocytes expand during post-
transplant CMV reactivation and likely participate in the
immune response to CMV [3]. It has been suggested that
during immune response to CMV both γδ TCR cross-
reactivity and NKG2D ligands confer cross-protection
against tumor cells [8-10]. Here we report a case of fulmin-
ant CMV reactivation after second allogeneic stem cell
transplantation as treatment for CLL. Despite expansion of
donor Vδ1+ T lymphocytes up to 25% of all circulating
peripheral blood lymphocytes, no reactivity against relapsing
B-CLL could be observed.
Case presentation
A 48-year-old patient was diagnosed with stage I (Rai
classification) CLL in 2002 with unmutated heavy chain
immunoglobulin. After 4 months of observation, he re-
quired conservative immunochemotherapy for progressive
leukocytosis and lymphadenopathy (six cycles Fludarabine).
In 2006, he underwent allogeneic hematopoietic stem celld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Time course of γδ T cell expansion after transplantation (Tx). γδ T cell frequencies among total lymphocytes are displayed in
relation to virologic responses (A) and in relation to donor chimerism (B). Virologic responses were measured by pp65 antigen detection in the
patient’s blood (pp65 positive per 400.000 leukocytes analysed). For determination of donor chimerism, microsatellite variable-number-of-tandem
repeat of peripheral blood leukocytes was analyzed using standard techniques [11].
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normalization of blood counts, regression of adenopathy,
and a 6-months progression-free interval. Donor and
recipient were CMV+, however, reactivation was not ob-
served. In March 2007, due to declining donor chimerism,
he was given donor lymphocyte infusions which, however,
could not prevent clinical relapse of CLL four months later.
Several cycles of immunochemotherapy (Rituximab alone
or in combination with Fludarabine or Bendamustine) and
donor lymphocyte infusions led to stabilization for about
one year, when a second relapse of B-CLL occurred. In
October 2011, after successful re-induction, the patient
again underwent additional allogeneic hematopoietic stem
cell transplantation, now from an unrelated donor. Main
complications after this second allogeneic transplantation
were repetitive CMV reactivations, which were treated with
four cycles of antiviral therapies including 2x Ganciclovir,
Foscarnet, and Cidofovir for CMV treatment. CMV reacti-
vation resolved in March 2012. No CMV specific CD8+Figure 2 Vδ9– γδ T cells expanded in the patient’s blood after transp
panel) with donor γδ T cells recovered from the patient (right panel) 9 mo
anti- pan TCR γδ (clone 11 F2) and FITC-conjugated anti-Vδ9 (Beckman Cou
of gated Vδ9+ (upper gate) and V9δ– (lower gate) γδ T cells among all lymdonor T cells could be observed by tetramer staining (data
not shown), but frequencies of donor γδ T lymphocytes
rose up to 25% of all circulating peripheral lymphocytes
(Figure 1A). It is likely that T lymphocytes expanded during
post-transplant CMV reactivation and participated in the
immune response to CMV [3]. Of note, the patient showed
no CMV reactivation after the first allogeneic transplant-
ation, and frequencies of γδ T lymphocytes had not in-
creased (3% and 4% of peripheral lymphocytes measured at
11 months and 1 month before second transplantation, re-
spectively). Despite expanded donor γδ T cell counts, we
observed a concomitant decline of donor chimerism and
progressive lymphadenopathy (Figure 1B).
Next, we sought to investigate the source, phenotype
and reactivity of the expanded γδ T lymphocytes in
more detail. First, we compared γδ T lymphocytes
among donor and recipient lymphocytes. While almost
all γδ T cells in peripheral blood of the stem cell donor
were Vδ9+, the vast majority (88%) of donor γδ T cellslantation. Flow cytometric comparison of donor lymphocytes (left
nths after transplantation. Samples were stained with PE-conjugated
lter cat. # PNIM1463). Numbers next to quadrants indicate percentage
phocytes.
Figure 3 Expanded γδ T cells in the patient’s blood are Vδ1+ γδ T cells. Further flow cytometric characterization of donor γδ T cells recovered
from the patient 9 months after transplantation. Ficoll-purified blood samples were stained with PE-Cy7-conjugated anti CD3 (BD bioscience, clone
SK7), PC5-conjugated Vδ9 (Beckman Coulter cat. # PNA63663), and FITC-conjugated Vδ1 (Thermo Scientific, clone TS8.2, cat. # EN-TCR2730). Numbers
next to quadrants indicate percentage of gated Vδ9+ (left panel) or Vδ1+ (right panel) γδ T cells among all CD3+ lymphocytes.
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transplantation were Vδ9– (Figure 2). We suspected that
the expanded T lymphocytes were Vδ1+ cells, which are
known for CMV-reactivity [6]. Specific flow cytometric ana-
lysis confirmed that indeed 24% of all CD3+ lymphocytes
expressed the Vδ1+ chain on their cell surface (Figure 3).
Since donor chimerism had declined in spite of expanded
donor γδ T cell counts, we tested the reactivity of FACS-
sorted γδ T lymphocytes from the patient against relapsing
B-CLL. At the same time, in vitro killing of CMV-infected
human foreskin fibroblasts (HFF) was assessed (Figure 4).
Interestingly, freshly ex vivo isolated γδ T lymphocytes


















Figure 4 Cytotoxicity assay of patient’s γδ T cells. Specific lysis of sorte
patient’s B-CLL. Total γδ T cells were sorted from patient’s blood samples u
separation using a FACS Aria cell sorter 9 months after transplantation. At t
positive signals using PerCPCy5.5-conjugated CD19 (clone 5J25C1) and PE-
release cytotoxicity assay was performed by using sorted γδ T cells as effec
(B) autologous tumor cells as targets. After 51Cr-labeling, target cells were w
10% foetal calf serum, 100 U/ml penicillin/streptomycin, 1 mM sodium pyru
1.25×105/ml) were pipetted in triplicates at three effector to target (E/T) rat
of target cell solution (1×105/ml). The assay was incubated for 20 hours. Th
harvested. Specific cytotoxicity was measured by determining released 51Cr
without effector cells. Maximal values were obtained by lysing target cells
spontaneous release / maximum release - spontaneous release x 100. Generat
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
UL11-V5 mutant [12] at an m.o.i. of 1 for 120 h prior to in vitro killing assayshowed a titratable specific lysis of CMV infected human
fibroblasts, but not against his own freshly sorted leukemia
cells. It is tempting to speculate that the patient’s B-CLL
was not recognized because it expressed too low levels of
NKG2D ligands such as MIC-A, MIC-B, or ULBP-proteins
on its cell surface. Indeed, flow cytometric revealed lacking
expression of these proteins on the cell surface of the
patient’s B-CLL cells (data not shown).
Conclusions
Our observations support the view that reactivity against
CMV-infected cells was the driving force for Vδ1+ γδ T
















d γδ T cells versus (A) CMV-infected human foreskin cells or (B) versus
sing PE-conjugated anti pan γδ TCR (clone 11 F2) after Ficoll
he same time, B-CLL cells were sorted according to size and for
Cy7-conjugated CD20 (clone L27). Cytotoxicity assay: 51chromium (51Cr)
tors and either (A) CMV-infected primary human foreskin fibroblasts or
ashed and resuspended in medium (RPMI1640 supplemented with
vate, and 2 mM glutamine). 100 μl of effector cells (1×106/ml –
ios (20:1, 10:1, and 2.5:1) in V-bottom microtiter plates containing 50 μl
e plates were centrifuged and 25 μl of cell-free supernatants were
. Background values were determined by incubating target cells
with Triton X-100. Specific lysis was calculated by: experimental release -
ion of positive control target cells by HFF infection: HFF were cultured
serum (FCS) and antibiotics. Cells were infected with HCMV TB40/E
.
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blood nor in the patient’s blood before second transplant-
ation. This argues for a contribution of Vδ1+ cells against
CMV reactivation after transplantation, which is in line
with recent literature [3]. However, the expanded Vδ1+
cells were unable to kill autologous tumor cells in vitro
and likely also in vivo as the lymphoma was progressing.
Taken together, our findings do not match the suggested
strong correlation of expanded Vδ1+ T cells and favorable
disease outcome in untreated B-CLL patients [2].
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